Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects
| Autor: | Hanna Trocha, Reinhold E. Schmidt, M. Beniowski, Joep M. A. Lange, Gerd Fätkenheuer, Heiko Jessen, Daniel H. Blanckenberg, Andrzej Horban, Waldemar Halota, Robin Wood, Anna Boroń-Kaczmarska |
|---|---|
| Přispěvatelé: | Infectious diseases |
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty Nevirapine Immunology HIV Infections Biology Gastroenterology Zidovudine immune system diseases Abacavir Antiretroviral Therapy Highly Active Internal medicine medicine Humans Hydroxyurea Immunology and Allergy Treatment Failure Nucleoside analogue Reverse-transcriptase inhibitor virus diseases Lamivudine Middle Aged Viral Load Virology CD4 Lymphocyte Count Regimen Treatment Outcome Infectious Diseases HIV-1 RNA Viral Reverse Transcriptase Inhibitors Female Viral load medicine.drug |
| Zdroj: | AIDS (London, England), 18(4), 631-640. Lippincott Williams and Wilkins |
| ISSN: | 0269-9370 |
| DOI: | 10.1097/00002030-200403050-00007 |
| Popis: | Objective: To examine the effect of adding nevirapine (NVP) and/or hydroxyurea (HU) to a triple nucleoside analogue reverse transcriptase inhibitor (NRTI) regimen in terms of efficacy and tolerability. Methods: HIV-1-infected, treatment-naive adults were randomized, using a factorial design, to add NVP and/or HU to the triple NRTI backbone of zidovudine plus lamivudine plus abacavir. Primary endpoint was treatment failure, defined as having plasma HIV RNA levels > 50 copies/ml after week 24, or discontinuation of randomized treatment. Follow-up was 72 weeks Results: For the 229 subjects, median plasma HIV-1 RNA was 4.61 log(10) copies/ml and median CD4 cell count was 269 x 10(6) cells/l. NVP users reached plasma HIV-1 RNA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|